MedTrace Logo

CYPRESS Efficacy and Safety Study Extension

NCT04947735 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-05-05

No results posted yet for this study

Summary

This is an open-label, controlled, multisite, two-arm parallel group clinical trial of 36-month duration to evaluate the continued safety and efficacy of SightGlass Vision Diffusion Optics Technology (DOT) Spectacles in reducing the progression of juvenile myopia.

Conditions

  • Juvenile Myopia
  • Myopia

Interventions

DEVICE

Novel spectacle lens design

Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia

DEVICE

Spectacle lenses

Single vision, impact resistant spectacle lenses

Sponsors & Collaborators

  • SightGlass Vision, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-19
Primary Completion
2026-10-31
Completion
2026-12-31
FDA Device
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04947735 on ClinicalTrials.gov